Pfizer Inc. (NYSE:PFE) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 48,507,825 shares, a decline of 7.1% from the August 15th total of 52,192,249 shares. Approximately 0.8% of the company’s shares are sold short. Based on an average daily trading volume, of 18,845,697 shares, the short-interest ratio is presently 2.6 days.
In other news, insider Laurie J. Olson sold 10,214 shares of the business’s stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at $2,979,552. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Alexander R. Mackenzie sold 25,642 shares of the business’s stock in a transaction that occurred on Friday, August 3rd. The shares were sold at an average price of $39.51, for a total value of $1,013,115.42. Following the transaction, the insider now directly owns 127,954 shares in the company, valued at $5,055,462.54. The disclosure for this sale can be found here. Insiders have sold 761,230 shares of company stock worth $29,054,690 over the last three months. Insiders own 0.06% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the business. Ballew Advisors Inc bought a new position in shares of Pfizer during the first quarter valued at $102,000. Earnest Partners LLC bought a new position in shares of Pfizer during the fourth quarter valued at $105,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Pfizer during the fourth quarter valued at $118,000. Fort L.P. bought a new position in shares of Pfizer during the second quarter valued at $121,000. Finally, Delpha Capital Management LLC bought a new position in shares of Pfizer during the fourth quarter valued at $126,000. 68.91% of the stock is currently owned by institutional investors and hedge funds.
NYSE PFE opened at $43.26 on Thursday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16. Pfizer has a twelve month low of $33.20 and a twelve month high of $43.68. The company has a market cap of $255.74 billion, a P/E ratio of 16.31, a PEG ratio of 2.06 and a beta of 0.96.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company had revenue of $13.47 billion for the quarter, compared to analyst estimates of $13.30 billion. During the same period in the previous year, the company posted $0.67 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. research analysts predict that Pfizer will post 2.99 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were given a dividend of $0.34 per share. The ex-dividend date was Thursday, August 2nd. This represents a $1.36 annualized dividend and a dividend yield of 3.14%. Pfizer’s dividend payout ratio is presently 51.32%.
PFE has been the topic of several research analyst reports. Societe Generale reissued a “neutral” rating and set a $39.00 target price on shares of Pfizer in a research note on Wednesday, May 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Thursday, June 7th. They set an “overweight” rating and a $45.00 target price on the stock. Credit Suisse Group set a $39.00 target price on Pfizer and gave the company a “neutral” rating in a research note on Monday, June 11th. Morgan Stanley reissued a “buy” rating and set a $43.00 target price on shares of Pfizer in a research note on Monday, June 11th. Finally, Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Tuesday, July 3rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.89.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Further Reading: What is a Tariff?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.